Viadur

DUBLIN, Ireland -- Prostate Cancer Therapeutics Analysed: a Solid Presentation of the Exciting and Rapidly Evolving Area

Research and Markets (http://www.researchandmarkets.com) has announced the addition of Basic Platform Report: Prostate Cancer to their offering.

This "Basic Platform Report: Prostate Cancer", provides a complete and systematic description of the current market of already established, as well as new innovative therapies for the treatment of prostate cancer.

In this informative report, extensive presentations of more than 200 selected companies active in this field are included.

The aim of this report has been to review the cancer research activities and partnerships in different therapeutic strategies.

Hundreds of pipeline drugs and a majority of alliances are described.

Each company profile contains contact data, a short description of the company, partnership activities, pipeline, patents and description of products already at market.

With the help of the complete company index of more than 200 firms and collaboration tables, any player in the field can be easily tracked down.

This "Basic Platform Report: Prostate Cancer" is an excellent source of information that provides a solid presentation of the exciting and rapidly evolving area of prostate cancer therapeutics.

Some of the drugs included in the report:

Avodart, Zoladex, Proscar, Casodex, Taxotere, Satraplatin, Plenaxis, EULEXIN, Trelstar Depot, Trelstar LA, Viadur, Gleevec, Avastin, Herceptin, Atrasentan, Acapodene, Actimid, OSI-461, Revimid, Eladem, GTI-2501, ILX-651, calcitrol, Genasense, Provenge , GVAX, SGN-15, Thalomid, Velcade, Lupron Depot, Histrelin, Eligard, ILX651, Vitaxin, J591, CG7870, BBR-3576, PCK3145, Leuvectin, Leuprolide, ProMaxx-100, Osaterone, Prinomastat, BLP25, Metaret, Chimax, Drogenil, Flutamide, EULEXIN, Onconase, IM862, MDX-010, Erbitux, Eladem, GTI-2040, Apomine, Eflornithine, Doxil, GTI-2501, Thalidomide, TG4010, KRX-0401, Yondelis, TRICOM Vaccine, Zarnestra

Some of the companies included in the report:

Aventis, Aeterna Laboratories Inc, Abbott Laboratories, Celgene, Cell Genesys, Cytogen Corporation, Dendreon, GlaxoSmithKline, GTx, Inc, Medimmune, Millennium Pharmaceuticals, Inc, Procyon BioPharma, Novacea Inc., Teikoku Hormone, Pfizer (Pharmacia), Paladin Labs/ Hydro Med Sciences, Novartis, Praecis Pharmaceuticals, Biomira, Spectrum Pharmaceuticals, ALZA, Medarex, ImClone,. BMS, Merck, Immuno-Designed Molecules (IDM), Lorus Therapeutics, ILEX Oncology, Keryx Biopharmaceuticals

Report Contents:

For more information visit http://www.researchandmarkets.com/reports/c4943

COPYRIGHT 2004 Business Wire
COPYRIGHT 2004 Gale Group